Council of Scientific and Industrial Research

Nicholas Piramal India Limited

Sudhir Srivastava

Satyawan Singh

Anil Kumar Dwivedi

Ram Pratap

Sunil Kumar Puri

Anil Kumar Rastogi

Omkar Prasad Asthana

Ram Chandra Gupta

Ram Raghubir

Raghwendra Pal

Onkar Prasad Asthana

Harsh Pati Thapliyal

Amiya Prasad Bhaduri

Guru Prasad Dutta

Pratima Srivastava

Vikash Chandra Pandey

Shio Kumar Singh

Jagdishwar Sahai Srivastava

Rajesh Kumar

Swati Ajay Piramal

Arvind Kumar Srivastava

Wahajul Haq

Anju Puri

Chandeshwar Nath

Deepak Raina

Ramesh Chandra

Hemant Kumar Singh

Girja Shankar

Depak Raina

Ajet Saxena

Puvvada Sri Ramachandra Murthy

Narender Tadigoppula

Narenda Singh

Arwind Kumar Srivastava

Poonam Gupta

Brijendra Kumar Tripathi

Nitya Nand

Puvvada Sri Ramchandra Murthy

Madhu Khanna

Jagdishwar Sahay Srivastava

Preeti Tiwari

Francis Joseph Pinto

Vijai Lakshmi

Mahendra Nath Srivastava

A bioactive fraction obtained fromthat is useful for the treatment of diabetes and dyslipidemia. This fraction can be provided in a pharmaceutical composition that is useful as antidiabetic and antidyslipidemic agent, or can be used in a method of treating diabetes and dyslipidemia in a subject. Also, a process for the preparation of bioactive fraction from. Isomeric xyloccensins and the preparation of such compounds. Also, pharmaceutical compositions comprising a therapeutically effective amount of such isomeric xyloccensins optionally along with one or more pharmaceutically acceptable carriers, additives, lubricant and diluents and the use of such pharmaceutical compositions in a method for treating dyslipidemia.

Pharmaceutical composition for treatment of diabetes and dyslipidemia

A combination kit for the treatment of malaria caused by() having individual doses of an anti-malarial agent, 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I) in the form of capsules; individual doses of the anti-malarial agent, chloroquine in the form of tablets; and instruction material for the administration of the two anti-malarial drugs. The combination kit is particularly suited for a 6 days treatment regimen where the treatment is rendered by five tablets containing 500 mg of chloroquine phosphate (equivalent to 300 mg base), three to be taken on day one and one each on days two and three; and five capsules containing 25 mg of 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I), one each to be taken on days two to six.

Combination kit used in the treatment of malaria

The present invention a novel use of primaquine derivative N-(3-ethylidinotetrahydrofuran-2-one)-N-(6-methoxy-8-quinolinyl)-1,4-pentanediamine in the treatment and controlling the spread of malaria. In particular, the present invention discloses a method of treatment of malaria by the use of primaquine derivative N-(3-ethylidinotetrahydrofuran-2-one)-N-(6-methoxy-8-quinolinyl)-1,4-pentanediamine as a gametocytocidal agent.

[object Object]

The present invention provides new uses of Gugulipid, an ethyl acetate extract of the resin of the plant, for controlling or preventing cognitive dysfunction, hyperglycemia and some infective conditions of the skin and a method of preparing Gugulipid by agitating the resin in shake flask assembly or sonicating assembly and preparing a solid or a creamy dosage forms.

Method of treating a cognitive memory dysfunction using Gugulipid

The invention provides novel inclusion complexes of highly potent opioid peptide of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin, pharmaceutical preparations containing these inclusion complexes of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin derivatives, the complexes being better soluble in water and having improved biopharmaceutical properties such as lesser toxicity, better analgesic action and non-addiction properties.

Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment

Growing community of inventors

Lucknow, India

Sudhir Srivastava